abacavir sulfate; dolutegravir sodium; lamivudine - Profile

What are the generic drug sources for abacavir sulfate; dolutegravir sodium; lamivudine and what is the scope of freedom to operate?

Abacavir sulfate; dolutegravir sodium; lamivudine is the generic ingredient in two branded drugs marketed by Viiv Hlthcare and is included in two NDAs. There are two patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Abacavir sulfate; dolutegravir sodium; lamivudine has one hundred and fifty-seven patent family members in thirty-five countries.

Summary for abacavir sulfate; dolutegravir sodium; lamivudine

International Patents:	157
US Patents:	2
Tradenames:	2
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for abacavir sulfate; dolutegravir sodium; lamivudine

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for abacavir sulfate; dolutegravir sodium; lamivudine

Constraining patent/regulatory exclusivity:

9,242,986*PED

Dosage:

TABLET;ORAL

Constraining patent/regulatory exclusivity:

9,242,986*PED

Dosage:

TABLET, FOR SUSPENSION;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Paragraph IV (Patent) Challenges for ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRIUMEQ PD	Tablets for Oral Suspension	abacavir sulfate; dolutegravir sodium; lamivudine	60 mg/5 mg/30 mg	215413	1	2023-03-31
TRIUMEQ	Tablets	abacavir sulfate; dolutegravir sodium; lamivudine	600 mg/50 mg/ 300 mg	205551	5	2017-08-14

US Patents and Regulatory Information for abacavir sulfate; dolutegravir sodium; lamivudine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	9,242,986*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes	8,129,385*PED				Y
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes
Viiv Hlthcare	TRIUMEQ PD	abacavir sulfate; dolutegravir sodium; lamivudine	TABLET, FOR SUSPENSION;ORAL	215413-001	Mar 30, 2022		RX	Yes	Yes

International Patents for abacavir sulfate; dolutegravir sodium; lamivudine

Country	Patent Number	Title	Estimated Expiration
Austria	E516026
Australia	2006239177	Polycyclic carbamoylpyridone derivative having HIV integrase inhibitory activity
Australia	2006307101	Polycyclic carbamoylpyridone derivative having inhibitory activity on HIV integrase
Brazil	PI0610030	composto, processo para a preparação de um composto, método de tratamento de uma infecção por hiv em um humano, uso de um composto, e, composição farmacêutica

Supplementary Protection Certificates for abacavir sulfate; dolutegravir sodium; lamivudine

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2465580	132021000000098	Italy		PRODUCT NAME: CABOTEGRAVIR(VOCABRIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1481, 20201221
1874117	C201430032	Spain		PRODUCT NAME: DOLUTEGRAVIR O UNA SAL O SOLVATO DEL MISMO FARMACEUTICAMENTE ACEPTABLE, INCLUIDA LA SAL SODICA DE DOLUTEGRAVIR.; NATIONAL AUTHORISATION NUMBER: EU/1/13/892; DATE OF AUTHORISATION: 20140116; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/13/892; DATE OF FIRST AUTHORISATION IN EEA: 20140116
2465580	2021C/519	Belgium		PRODUCT NAME: VOCABRIA-CABOTEGRAVIR; AUTHORISATION NUMBER AND DATE: EU/1/20/1481 20201221
1874117	202 50006-2014	Slovakia		PRODUCT NAME: SODNA SOL DOLUTEGRAVIRU; REGISTRATION NO/DATE: EU/1/13/892/001 - EU/1/13/892/002 20140121

Investment Analysis on the Pharmaceutical Trio: Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine

Last updated: February 3, 2026

Summary

This analysis evaluates the market landscape, investment viability, and future financial trajectory of the combination therapy of abacavir sulfate, dolutegravir sodium, and lamivudine – a cornerstone in antiretroviral therapy (ART) for HIV treatment. Marching through current market dynamics, regulatory status, competitive landscape, and forecasted trends, it offers clarity for stakeholders considering or analyzing investments in this segment.

---

What Are the Current Market Dynamics for the Abacavir–Dolutegravir–Lamivudine (ABC/DTG/3TC) Regimen?

Market Size and Growth

• The global HIV treatment market was valued at approximately $27 billion in 2022, with projections reaching $36 billion by 2027 (CAGR ~6.0%) [1].
• The ABC/DTG/3TC regimen is a leading first-line therapy, especially after the 2019 WHO guidelines recommended integrase inhibitors as preferred options [2].

Market Drivers

Driver	Impact & Evidence
Rising HIV prevalence globally	Over 38 million people living with HIV globally [3]
Policy shift toward integrase inhibitors	DTG-containing regimens favored for efficacy and tolerability [4]
Generic drug availability	Decreases in cost, increasing accessibility in LMICs [5]
Patent expirations and biosimilar development	Expanded market penetration and price competition [6]

Key Market Players

Company	Role	Market Share
Gilead Sciences	Originator, Co-formulated ABC/3TC, Biktarvy (DTG-based)	~45%
ViiV Healthcare	Led by GSK, with Dolutegravir-based formulations	~35%
Mylan (Now Viatris), Teva	Generics providers	Remaining ~20%

---

Financial Trajectory: Revenues, Growth, and Investment Indicators

Historical Revenue Breakdown (2020–2022)

Product/Segment	2020 Revenue (USD billion)	2022 Revenue (USD billion)	CAGR (2020–2022)
Gilead’s ABC/3TC and Biktarvy	$10.2 billion	$13.8 billion	17.4%
ViiV’s DTG-based therapies	$8.1 billion	$10.9 billion	20.4%
Total global ART market	$20 billion	$27 billion	10–12% annually

Forecasted Revenue and Market Share (2023–2027)

Year	Expected Market Size (USD billion)	Major Therapy Contributions	Notes
2023	$36 billion	ABC/DTG/3TC (~60%), others	Market penetration continues
2025	$45 billion	Increasing demand for generic formulations	Patent cliffs facilitate generics
2027	$54 billion	Biotech and biosimilar entrants influence	Competition intensifies

Investment Indicators

• Patent expiration timelines: Gilead’s Biktarvy patents expire around 2025, fostering generic entry [7].
• Regulatory approvals: Increased approvals for fixed-dose combinations (FDCs) enhance market reach [8].
• R&D pipeline: Several firms develop long-acting injectables and novel combinations, potentially disrupting traditional oral regimens [9].

---

Comparison of Key Market Players and Product Portfolios

Company	Core Products	Estimated Revenue (USD, 2022)	Focus Areas	Patents & Approvals
Gilead Sciences	Biktarvy, Descovy, Truvada (oral formulations)	$13.8 billion	Strong oral and injectable ART pipelines	Key patents up for expiration in 2025
ViiV Healthcare	Dolutegravir-based products (Tivicay, Juluca, Juluca), long-acting injectables	$10.9 billion	Long-acting injectables, pediatric formulations	Advanced pipeline; multiple approvals
Mylan / Viatris	Generic ABC/3TC and DTG-based formulations	Variable, ~$1–2 billion	Oral generics, biosimilars	Focused on markets with patent expiry

---

Recent Policy and Regulatory Trends Impacting Investment

Policy/Regulation	Impact	Source/Date
WHO 2019 Guidelines	Increased adoption of DTG-based regimens, boosting demand	WHO, 2019 [2]
US FDA fast track approvals	Accelerates pipeline development, reduces time-to-market	FDA, 2021 [10]
Patent law enforcement in emerging markets	Influences generic market entry timelines	WTO, 2022 [11]
Price negotiation policies in LMICs	Pressure on pricing dynamics, incentivize biosimilares	UNAIDS, 2022 [12]

---

Market Challenges and Risks

Challenge/Risk	Explanation	Potential Impact
Patent cliffs	Expiry of key patents could commoditize products	Revenue decline; increased generics
Pricing pressures in LMICs	Government negotiations limit profit margins	Reduced profitability
Competition from new modalities (long-acting injectables)	Disrupts traditional oral regimen market	Market share shift
Regulatory delays and hurdles	Slows approval of new formulations or biosimilars	Investment delays or costs
Supply chain disruptions	COVID-19 pandemic revealed vulnerabilities	Production costs, delays

---

Comparison of Investment Potential: Abacavir Sulfate, Dolutegravir Sodium, and Lamivudine

Parameter	Abacavir Sulfate	Dolutegravir Sodium	Lamivudine
Patent Status	Near expiry (~2023–2025 in key regions)	Active patent expiration (~2025)	Generic, widely available
Market Share in HIV Regimens	~30% (part of ABC/3TC/DTG therapy)	Leading integrase inhibitor (~60%)	High, global access
R&D Pipeline	Mostly mature; biosimilars emerging	Long-acting formulations under review	Maturity, biosimilars widespread
Regulatory Approvals	Established; some regional restrictions	Expanding, including injectable forms	Ubiquitous
Investment Considerations	Patent expiry risk; biosBlockades emerging	Growth in long-acting variants; patent expiry	High liquidity; generics market

---

Key Trends and Forward-Looking Outlook

• Growing adoption of integrase inhibitors, especially DTG-based regimens, cement the long-term market trajectory.
• Patent expirations in mid-2020s will catalyze significant market entry by biosimilars and generics, pressuring margins but expanding market volume.
• Emerging technologies such as long-acting injectables (cabotegravir, Rilpivirine) seek to replace daily oral regimens, potentially shifting investment focus.
• Market expansion in LMICs driven by lowered costs, international health initiatives, and patent expiries offers growth avenues.
• Pipeline innovations, including fixed-dose combination (FDC) pills and novel delivery mechanisms, are critical valuation drivers in the mid to long term.

---

Comparison Table: Investment Viability in the ABC/DTG/3TC Market

Feature	High Potential	Moderate Potential	Low Potential
Patent Expiry Risk	Yes	No	No
Market Penetration in LMICs	Yes	Limited	Limited
Pipeline Innovation	Yes (Long-acting injectables)	Limited	Limited
Regulatory Favorability	Moderate	High	Low
Competitive Landscape	Fierce, with biosimilars	Moderate	High

---

Conclusion: Investment Outlook

The combination of abacavir sulfate, dolutegravir sodium, and lamivudine currently sit at a strategic inflection point. The growth prospects are robust, fueled by increasing demand, international policy shifts favoring integrase inhibitors, and expanding access in developing markets. However, patent expirations and rising competition necessitate careful risk assessment.

Speculators and investors should recognize the following:

• Near-term opportunity exists in generic markets post-patent expiry, with potential for volume-driven revenue growth.
• Long-term growth hinges on innovation such as long-acting formulations and expanding biosimilar pipelines.
• Region-specific strategies are vital, considering regulatory and price negotiation landscapes.

Given these factors, the outlook remains positive with cautious contingency planning for patent cliffs and competitive pressures.

---

Key Takeaways

• The HIV ART market is poised for sustained growth, with the ABC/DTG/3TC regimen at its core.
• Patent expiries around 2025 will likely lead to increased biosimilar and generic market activity.
• Investment risks include pricing pressures, regulatory delays, and emerging competition from novel therapies.
• Long-acting injectable formulations represent a transformative innovation, likely elevating future market value.
• Stakeholders should prioritize pipeline developments, regional market policies, and patent landscapes in investment strategies.

---

FAQs

Q1: What is the current patent status of abacavir sulfate, dolutegravir sodium, and lamivudine?
A: Patent protections for abacavir sulfate and dolutegravir sodium are set to expire approximately between 2023 and 2025 in many jurisdictions. Lamivudine’s patents have mostly expired, with generics widespread globally [7][8][10].

Q2: How do patent expirations influence market investment opportunities?
A: Patent expiration enables biosimilar and generic competitors to enter the market, often leading to significant price reductions, increased volume sales, and investment in manufacturing and distribution infrastructure.

Q3: What are the potential growth markets for these drugs?
A: Expanding HIV treatment programs in Africa, Asia, and Latin America, driven by international health initiatives, are key markets with high growth potential, especially for affordable generics.

Q4: How might emerging long-acting formulations impact the current market?
A: Long-acting injectables, such as cabotegravir and Rilpivirine, have the potential to replace daily oral regimens, offering competitive advantages and creating new investment opportunities.

Q5: How does competitive pressure from biosimilars affect revenue projections?
A: Biosimilar entry typically lowers prices and margins but increases market access and volume, requiring strategic balance in investment to capitalize on cost advantages while managing revenue declines.

---

References

[1] MarketWatch, “Global HIV Treatment Market Size, Share & Trends Analysis Report,” 2022.
[2] WHO, “Guidelines for the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection,” 2019.
[3] UNAIDS, “Global AIDS Update 2022,” 2022.
[4] The Lancet, “Treatment guidelines for HIV,” 2019.
[5] GlobalData, “HIV/AIDS Therapeutics Market Analysis,” 2021.
[6] FDA, “Biosimilar and Generic Drug Approvals,” 2022.
[7] Gilead Sciences, “Financial Reports,” 2022.
[8] PatentScope, “Patent filings for ABC/3TC drugs,” 2022.
[9] Pharmaprojects, “Long-acting HIV formulations,” 2023.
[10] FDA, “New Drug Approvals 2021,” 2021.
[11] WTO, “Intellectual Property Rights and Generic Entry,” 2022.
[12] UNAIDS, “Pricing and Access Policies in Low-Income Countries,” 2022.